DDInter704 DDInter1925
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Everolimus {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Everolimus {u} (Compound) downregulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vemurafenib
Everolimus {u} (Compound) downregulates {v} (Gene) CLPP
CLPP {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Everolimus {u} (Compound) upregulates {v} (Gene) NXF1
NXF1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Everolimus {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Everolimus {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is regulated by {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Everolimus (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Vemurafenib (Compound)
Everolimus (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Vemurafenib (Compound)
Everolimus (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound)
Everolimus (Compound) downregulates CLPP (Gene) and CLPP (Gene) is downregulated by Vemurafenib (Compound)
Everolimus (Compound) upregulates NXF1 (Gene) and NXF1 (Gene) is downregulated by Vemurafenib (Compound)
Everolimus (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Everolimus (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is regulated by IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Vemurafenib (Compound)